Corteva Inc (CTVA) Stock Forecast & Price Target

Corteva is supported by a highly attractive valuation of about 6.5x EV/EBITDA on 2027E and an unlevered FCF yield near 10%, while its balance sheet should finish 2026 with roughly $0.5B of net cash after the Vylor spin. Its outlook is strengthened by a robust pipeline of new crop protection products and biologics, with management targeting about $800M of annual new-product revenue and roughly $1B of biologics uplift by 2029. With company-specific cost savings, improving farmer economics, and global exposure led by North America and Latin America, EBITDA could rise toward the top end of the $1.45B-$1.65B target range.

Corteva is facing a difficult crop chemicals backdrop, with limited volume growth, persistent generic deflation, and management’s own assumption of a 1% annual price decline during the 2027-2029 period signaling that pricing pressure may remain entrenched. The negative view is reinforced by commentary that the market could decline 4-5% in 2026, while weaker crop prices, softening farm income, and corn stocks-to-use near 15% versus a 10-year average of about 12% point to lower farmer spending and weaker planting incentives. The spun-off company may also lose some strategic leverage versus its pre-spin structure, especially in Brazil and other large-farm channels, while delays in new products, destocking, and synergy execution could weigh on returns.